Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06550531

Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)

The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Human Papilloma Virus Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Infertility Infertility, Female Urogenital Diseases

Age range

25 year–38 year

Sex eligibility

Female

Study type

Observational

Primary location

CHRU de Brest

Brest, 29609, France

Location status: Recruiting

Location contact

Sarah BOUEE

CONTACT

[email protected]

About this study

This is a single-center prospective study in the assisted reproduction center of Brest University Hospital. All new patients coming to consult will be offered participation in the study. The HPV test will be updated if it is older than 12 months. We will analyze stimulation results and pregnancy outcomes according to HPV status. Inclusions will take place over 3 years

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • all etiology of infertility AMH > ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months

Exclusion criteria

Age < 25 y Age > ou = 38 y AMH < 1.1 ng/ml patient under juridic protection rejection of participation

Treatment and study plan

Primary outcomes

  1. clinical pregnancy rate after fresh eSET by HPV status

    Time frame: 1 year

    A clinical pregancy is the visualisation of a gestational sac inside the uterus after 6 weeks of gestation

Secondary outcomes

  1. IVF issues

    Time frame: 1 year

    oocytes number, embryos number, fecondation rate, implantation rate

  2. Positive HPV rate

    Time frame: 1 year

    number of women who have a positive HPV test before IVF procedure

Study contacts

Contact information is provided by the study sponsor or research team.

Anne-Solenn JACAMON

CONTACT

[email protected]

Sarah BOUEE

CONTACT

[email protected]

02 98 22 39 70

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Impact of Human Papillomavirus Carriage on IVF/ICSI Results at Brest University Hospital

Acronym: HPV-AMP

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Aug 13, 2024
Registry last updated
Aug 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.